Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Hypertrophic Cardiomyopathy Clinical Trial

Official title:

Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03150342
• Other study ID #: 106057-E
• Status: Recruiting
• Phase: N/A
• First received: May 10, 2017
• Last updated: May 15, 2017
• Start date: May 8, 2017
• Est. completion date: June 30, 2018

Study information

• Verified date: May 2017
• Source: Far Eastern Memorial Hospital
• Contact: Szu-Ying Tsai, MD
• Phone: +886289227000
• Email: dorissyt[@]mail.femh.org.tw
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chest pain and myocardial ischemia are prevailing features in patients with hypertrophic cardiomyopathy (HCM). Recently introduced single-photon emission computed tomography (SPECT) cameras with solid-state cadmium-zinc-telluride (CZT) detectors have been shown to decrease imaging time and improved the imaging quality of gated myocardial perfusion imaging (MPI). The investigators also correlate the MPI parameters with echocardiographic parameters. This study is to examine the spatial distribution of stress perfusion abnormalities and tissue injury in patients with HCM using a CZT SPECT camera.

Description:

The investigators will retrospectively evaluate myocardial perfusion patterns and cardiac function with Thallium (Tl)-201 gated dipyridamole MPI in patients with clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016. The inclusion criteria included a spade-like configuration on left ventriculogram, or echocardiographic findings suggestive of HCM. The participants will be then divided into the following three groups: apical, concentric and septal forms. Regional perfusion would be analyzed using a 17-segment model from 0-4 degree (0=normal, to 4=absent perfusion); and summed stress score (SSS), summed rest score (SRS) and summed difference score (SDS) were calculated. Gated SPECT would be processed by quantitative gated SPECT (QGS) software (Cedars-Sinai Medical Center, Los Angeles, CA, USA) and ejection fraction phase analysis. Diastolic parameters would be also acquired by Doppler echocardiography, and correlated with MPI parameters.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 30, 2018
• Est. primary completion date: August 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016.

Exclusion Criteria:

• patient with prior myocardial ischemia, conduction abnormality, valvular disease or other cardiomyopathy

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• Hypertrophic Cardiomyopathy
• Hypertrophy
• Myocardial Perfusion Imaging

Intervention

Diagnostic Test:
• myocardial perfusion imaging
dipyridamole-stressed MPI scan using thallium-201

Locations

Country	Name	City	State
Taiwan	Far Eastern Memorial Hospital	New Taipei City

Sponsors (1)

Lead Sponsor	Collaborator
Far Eastern Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MPI results	including perfusion abnormalities, and ejection fraction phase analysis results	January 2013 and October 2016.